BioFactura Funded $16 Million Contract Option for its Smallpox Biodefense Therapeutic

Supports clinical manufacturing for an upcoming first-in-human Phase 1 trial FREDERICK, Md., Oct. 2, 2023 /PRNewswire-PRWeb/ -- BioFactura, Inc. today announced a contract option activation of over $16 million by the Biomedical Advanced Research and Development Authority (BARDA) part of...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Tags: CON Source Type: news